Chronic kidney disease (CKD) affects millions of people worldwide. CKD is a progressive disease with large unmet medical needs, and growing in prevalence due to the epidemic of type 2 diabetes. Vidasym has two clinical stage drugs for treatment of CKD: a novel vitamin D receptor modulator (VDRM), and a non-absorbed, calcium-free, aluminum-free, highly effective phosphate binder. There are on-market products in both categories with important limitations contributing to significant unmet medical need. The advantages of Vidasym's candidate molecules are clearly defined, and offer significant potential benefit to patients, payers, and physicians. Vidasym has also identified several VDRM drug candidates for additional pharmaceutical markets, such as cancer-related thrombosis, osteoporosis and psoriasis.